BofA/Merrill Lynch Upgrades ResMed (RMD) to Buy
- Stock futures rise as flurry of deal activity boosts confidence
- AT&T (T) to Acquire Time Warner (TWX) for $107.50/Share
- Rockwell Collins (COL) to Acquire B/E Aerospace (BEAV) for $6.4B
- TD Ameritrade (AMTD) to Acquire Scottrade in $4B Cash & Stock Deal
- Oil prices fall as Iraq resists joining output cut
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
BofA/Merrill Lynch upgraded ResMed (NYSE: RMD) from Neutral to Buy.
Shares of ResMed closed at $64.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA/Merrill Lynch Downgrades Electronic Arts (EA) to Neutral
- How Technology is Tackling the World's Greatest Healthcare Challenges in the Era of Personalized Medicine, at the Digital Health Summit at CES 2017
- Notable Mergers and Acquisitions 10/20: (GWR) (XGTI) (STI)
Create E-mail Alert Related CategoriesUpgrades
Related EntitiesMerrill Lynch, Bank of America
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!